Most cancer patients never hear the truth: access to care doesn’t mean access to the best care.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down why standard cancer treatment often fails to deliver long-term results. Built around population averages, insurance billing, and hospital revenue models — not the patient — most protocols overlook the thousands of genetic and immune markers that determine how your body responds to treatment.

Dr. Prato explains how multi-omics deep mapping (DNA, RNA, immune, and spatial biology) reveals the true drivers of your cancer and how immune-centric, precision-built care can transform outcomes. This episode dives into how Envita’s precision ecosystem custom-builds drug combinations, delivery systems, and immune retraining to help patients achieve durable remission — not just short-term control.

🎯 What You’ll Learn in This Episode:
• Why standard of care treats population averages, not individuals
• How multi-omics testing (DNA, RNA, immune, spatial biology) changes treatment outcomes
• The difference between cytostatic (slowing) and cytotoxic (killing) therapies
• How immune-centric care “turns cold tumors hot” for better response
• Why adaptive real-time monitoring helps prevent relapse
• The key questions every cancer patient should ask before starting treatment

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493